Phase 2, Single-Arm Trial of Comprehensive Ablative Bridging Irradiation (CABI) Prior to CD19 CAR-T Cell Therapy in High-Risk, Relapsed or Refractory Large B Cell Lymphoma in Patients With Bulky Disease
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 13 Mar 2025 Planned End Date changed from 1 Jul 2026 to 1 Nov 2026.
- 13 Mar 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Nov 2025.
- 22 Aug 2024 Planned End Date changed from 1 Oct 2027 to 1 Jul 2026.